Biogen Idec’s ALS drug Failed Final Clinical Trial


Biogen Idec’s ALS drug Failed Final Clinical Trial

As per reports, it has been recently revealed that Biogen Idec was unable to get through the last clinical trial of its ALS drug. Researchers have acknowledged the loss by saying that it was not only shocking but discouraging as well.

Dr. Robert Brown, who is an ALS researcher, was of the view that they have worked hard on the drug, but they failed a crucial test. However, this does not mean that no more research will take as the disease needs an effective treatment.

While talking about the last and final clinical trial, which could not attain success, Brown said that they had enrolled 943 people, who were suffering from amyotrophic lateral sclerosis. They were enrolled to test the efficacy of their once-promising dexpramipexole drug.

After carrying out the study, Brown said that they did not find any sort of benefit from the drug. And, then only, they decided to halt the programme. "While these results were not what we expected, we hope this data will provide a foundation for future ALS research", said Dr. Douglas Kerr, who is the director of neurodegeneration clinical research at Biogen.

The failure does not mark an end to the research, said Kerr, as they still have been working on it.


Latest News

Hackers cut access to some of the world's best known websites on Friday
Dinosaur bones found in Alaska’s Denali National Park
Californians to vote on marijuana legalization measure next month
Microsoft posts $20.5B revenue for July-September 2016 quarter
Tesla is equipping its vehicles with hardware required to make them fully self-d
Orbital’s Antares rocket returns to flight with successful cargo launch
Twitter Would Need New Strategy for Growth as Salesforce Walks Out of Deal
Verizon versions of Google Pixel will get all updates “simultaneously” with non-
Samsung Galaxy Note 7 handsets banned from airline flights in US
HP plans to cut up to 4,000 jobs in next 3-4 years
Valve shows off its new prototype SteamVR controller
AT&T, T-Mobile stop exchanges for new Samsung Galaxy Note 7 handsets